Drug intelligence / Profile preview

amoxicillin + clavulanate + gentamicin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination antibiotic therapy consisting of amoxicillin (a penicillin-like antibiotic), clavulanate (a beta-lactamase inhibitor), and gentamicin (an aminoglycoside antibiotic). This combination provides synergistic antibacterial activity against a wide range of bacteria, including those resistant to amoxicillin alone. It is particularly useful for treating severe bacterial infections such as pneumonia, serious skin and soft tissue infections, and complicated urinary tract infections.

Brand names: Augmentin
Other names: Co-amoxiclav + GentamicinAmoxicillin/clavulanate + Gentamicin

Targets

16S rRNA (16S ribosomal RNA)β-lactamasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on amoxicillin + clavulanate + gentamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + clavulanate + gentamicin.

Explore the full profile